Besides their well - known function
as effector cells in allergic responses, mast cells were reported to play a critical role in innate immunity and to exert important stimulatory but also suppressive functions in adaptive immune responses.
Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells
as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels
She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells
as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.
The in vitro boosted effector cells were washed once with HBSS and then resuspended in CRPMI and used
as effector cells in the cytotoxicity and apoptosis assays (below).
These are led by activated T helper 2 (TH2) cells and type 2 innate lymphoid cells (ILC2s), together known
as effector cells.
Not exact matches
In reaction to infection or inflammation, immune system
cells known
as effector T
cells (Teffs) undergo rapid changes - arming themselves and diversifying into groups that target specific diseased
cells.
We suspect that this «junk» HIV can act
as a decoy and draw attention away from the «real» virus hiding in the
effector memory T -
cells,» she said.
«It was once believed that
effector and memory
cells arose
as two distinct populations, with some
cells initially fated to be
effector type and some to be memory,» McDonald said.
As the interleukin - 2 levels drop,
effector cells can turn on a protein called Bcl - 6.
Effector T
cells incite GvHD when they become overactive
as the patient's immune system starts to rebuild itself from the donor stem
cells.
The «kick - and - kill» paradigm is aimed at combining latency reversing agents (LRA) with immune
effectors, such
as T -
cells, to wake up the virus and kill the reactivated
cells.
This study shows how exhausted T
cells do not maintain a durable switch to an
effector T
cell profile, although in the clinic, checkpoint inhibitors are well tolerated and their side effects such
as autoimmunity are usually manageable.
Our experts in mucosal vaccine delivery have established in vitro and in vivo models to assess the activity of adjuvants and vaccine formulations on innate and adaptive immune
cells,
as well their capacity to stimulate different
effector mechanisms of clearance.
These include examinations of the effect of antigen structure on the spectrum of cytokines produced after either in vivo or in vitro stimulation,
as well
as the ability to anergize Vα14 iNKT
cells in terms of cytokine production and
effector function by prior antigen challenge.
The things that we have demonstrated — such
as the fact that the vertical nanowires can deliver any biological
effector to any
cell type in a spatially selected fashion — have drawn interest from many different people, and we have been working with stem
cell institutes and others to demonstrate the unique utility of this particular platform.
Apoptosis has been implicated
as a T
cell - dependent immune
effector mechanism in various forms of organ graft rejection (29 — 31).
We have also have adopted a number of lines of study into the regulation of cytokine production and
effector cell responses such,
as cytotoxicity, in the response of Vα14 iNKT
cells to glycolipid antigens or IL - 12 from activated DCs.
Among the multiple p53 transcriptional targets, p21 stands out
as the main, although not exclusive,
effector of p53 - mediated
cell cycle arrest (8, 9, 10).
The most potent of these, known
as effector memory T
cells, are activated by a group of proteins known
as human leukocyte antigens (HLAs) on the surface of endothelial
cells lining the donated organ's blood vessels.
Activation of multiple signaling pathways may allow
cells to finely tune expression of
effector molecules
as well
as provide redundancy and resiliency.
For the candidate gene in the region, RSPO3, we demonstrated expression in key liver - resident
effector cells, such
as human and murine cholangiocytes and human hepatic stellate
cells.
Moreover, knock in animal models for syngeneic studies and allowing us to isolate transgenic armed
effector cells are developed in order to show proof of concept for the diverse applicability of our modular targeting systems including for tumor diseases, autoimmune diseases, GvHD, transplantation / rejection
as well
as viral infections.